Enliven Therapeutics, Inc. (ELVN) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology. The company is currently advancing two primary product candidates: ELVN-001 (BCR-ABL program for chronic myeloid leukemia) and ELVN-002 (HER2 program for solid tumors). Management has stated an intention to prioritize ELVN-001 and is exploring strategic alternatives for ELVN-002, with no plans to pursue its development beyond 2025.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(20.1) million | $(23.2) million | $(74.0) million | $(65.8) million |
| Net Loss Per Share | $(0.32) | $(0.48) | $(1.35) | $(1.43) |
| Operating Expenses | $25.1 million | $27.1 million | $85.4 million | $77.7 million |
| Cash & Marketable Securities | $477.6 million (as of Sept 30, 2025) | |||
| Accumulated Deficit | $317.5 million (as of Sept 30, 2025) | |||
| Debt | None outstanding |
Material Changes vs. Prior Period
- Capital Raise: In June 2025, the company completed a public offering raising approximately $230.0 million in gross proceeds ($216.2 million net). This significantly bolstered liquidity compared to the prior year.
- R&D Spend Shift: Total R&D expenses decreased by $3.1 million in Q3 2025 compared to Q3 2024. This was driven by a $6.1 million reduction in ELVN-002 costs due to the decision to explore strategic alternatives, partially offset by a $1.5 million increase in ELVN-001 costs due to clinical progression.
- Stock-Based Compensation: Stock-based compensation expense increased significantly, rising from $5.2 million in Q3 2024 to $7.2 million in Q3 2025, contributing to higher General and Administrative (G&A) expenses.
- Interest Income: Other income increased to $4.9 million in Q3 2025 from $3.9 million in Q3 2024, primarily due to higher interest income on a larger investment balance.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management expects cash, cash equivalents, and marketable securities of $477.6 million to be sufficient to fund operations for at least the next 12 months from the filing date.
- Strategic Focus: The company is shifting resources to prioritize the pivotal trial for ELVN-001. ELVN-002 development is being paused beyond 2025 while strategic alternatives are explored.
- Regulatory & Clinical Risks: Success depends on the safety and efficacy of ELVN-001 in Phase 1 trials. The company faces risks related to patient enrollment, particularly in Israel due to geopolitical conflict, and reliance on third-party manufacturers (including in China) which exposes the company to trade tensions and supply chain disruptions.
- Forward-Looking Statements: The filing contains extensive forward-looking statements regarding clinical trial timelines, regulatory approvals, and capital requirements, all of which are subject to significant uncertainty.
Investor Verification Checklist
- Verify the specific terms and status of "strategic alternatives" being explored for the ELVN-002 program.
- Confirm the timeline and enrollment progress for the ELVN-001 Phase 1 clinical trial, specifically regarding sites in Israel.
- Review the company's reliance on Chinese contract manufacturing organizations (CMOs) and the potential impact of U.S.-China trade policies on supply chains.
- Monitor the burn rate relative to the $477.6 million cash position to validate the 12-month liquidity runway.
- Check for updates on the "One Big Beautiful Bill Act" (OBBBA) tax implications, specifically regarding the reinstatement of immediate expensing for R&D expenditures.